Organon Revenue and Competitors

USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Organon's estimated annual revenue is currently $7.9B per year.(i)
  • Organon's estimated revenue per employee is $955,499
  • Organon's current valuation is $8.3B. (January 2022)

Employee Data

  • Organon has 8247 Employees.(i)
  • Organon grew their employee count by 5% last year.

Organon's People

NameTitleEmail/Phone
1
CIOReveal Email/Phone
2
Executive Director Business DevelopmentReveal Email/Phone
3
Associate VP, Commercial Operations and Established BrandsReveal Email/Phone
4
Associate VP, R&D Strategic Engagements & Vendor ManagementReveal Email/Phone
5
Executive Director, Women’s Health Business DevelopmentReveal Email/Phone
6
Associate VP QualityReveal Email/Phone
7
Chief Communications OfficerReveal Email/Phone
8
Associate VP HEORReveal Email/Phone
9
Associate VP, Established Brands and Regional Business DevelopmentReveal Email/Phone
10
Associate VPReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Organon?

Organon is a Dutch pharmaceutical company started in Oss the Netherlands. It is famous for "the Pil" a birthcontrol pil. Organon grew as a company and was taken over by Schering plough and later on by Merck and continues as MSD in the Netherlands. In the old days the compant was great, it used to be "gezellig" !

keywords:N/A

N/A

Total Funding

8247

Number of Employees

$7.9B

Revenue (est)

5%

Employee Growth %

$8.3B

Valuation

N/A

Accelerator

Organon News

2022-04-17 - Organon To Report First Quarter Results and Host Conference ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Apr 21, 2022--. Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5,...

2022-04-17 - Organon & Co. (NYSE:OGN) Downgraded by Zacks ...

Organon & Co. (NYSE:OGN) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...

2022-03-30 - Organon Enters into Global License Agreement to ...

Organon Enters into Global License Agreement to Commercialize Daré Bioscience's XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3818.4M8265-22%N/A
#2
$1184.4M84603%N/A
#3
N/A85166%N/A
#4
$2506.1M85240%N/A
#5
$2719.7M85585%N/A